Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
Kollagen- & Matrixuntersttzung: Beide Peptide frdern die Fibroblasten-Proliferation und Kollagensynthese und untersttzen damit die strukturelle Gewebeintegritt
And although she admits to feeling insecuredespite not showing it on airabout jumping headfirst into something so firmly outside her comfort zone, shes committed to becoming a member of this (often, boys) club
Sources Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021) The New England Journal of Medicine [accessed 10th February 2026] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (2022) Nature Medicine ] [accessed 10th February 2026] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4) (2021) JAMA ] [accessed 10th February 2026] Semaglutide 2.4 mg once weekly in adults with overweight or obesity, and type 2 diabetes (STEP 2 Trial) (2021) The Lancet ] [accessed 10th February 2026] Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg solution for injection in pre-filled pen (2024) Electronic Medicines Compendium (EMC): Patient Information Leaflet ] [accessed 10th February 2026] Wegovy (semaglutide) Summary of Product Characteristics (2024) Electronic Medicines Compendium (EMC) ] [accessed 10th February 2026] MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults (2024) GOV.UK ] [accessed 10th February 2026] Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity (SELECT Trial) (2023) PubMed / SELECT CVOT Overview [accessed 10th February 2026] A Research Study to Look at How Well Semaglutide Helps People Lose Weight (STEP UP Phase 3b) (2024) ClinicalTrials.gov ] [accessed 10th February 2026] Wegovy (semaglutide) Injection: Your Complete Guide to Wegovy Pen (2026) Novo Nordisk ] [accessed 10th February 2026] Semaglutide for managing overweight and obesity (2023) NICE ] [accessed 10th February 2026] Medically reviewed by reviewed by Tannaz Sohrabi (MPharm, PGDip, IP, MRPharmS) GPhC Number: 2225756 Last reviewed: 17th April 2026 Meet our medical professionals medical professionals Sunny Dhain Clinical Director Kamaldeep Kaur Pharmacist Prescriber Aaliyah Nelson Nutritional Coaching BSc (Hons) Nutrition: 47988 Standards first always always
It was a surprise that it was that much better
